CLL: Cello Health plc - Summary | Jitta

Cello Health plc

LON:CLL

Notice
Stock data is unavailable or the company’s delisted.
Price
£1.61
Loss Chance
58.4%
4.52JITTA SCORE
264.28%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (53)
Recent Business Performance (52)
Financial Strength (69)
Return to Shareholders (15)
Competitive Advantage (35)
Jitta Signs
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 105.70% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
4.52
264.28%
1.64
86.09%
1.64
86.09%
3.64
49.96%
4.52
72.81%
4.96
32.31%
COMPANY DESCRIPTION
Cello Health plc, together with its subsidiaries, offers marketing services in the United Kingdom, the rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment offers market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is based in London, the United Kingdom. As of August 11, 2020, Cello Health plc operates as a subsidiary of Value Demonstration UK Holdings Limited.